2025年阿福他酶α正版的价格是多少？

Afotalase α is a drug used for enzyme replacement therapy, developed by Alexion Pharmaceuticals (Alexion) of the United States, with the trade name Strensiq. The latest data in 2025 shows that the genuine price of 18mg/0.45mL/box of aftase alpha is approximately US$13,204, which is relatively high and has not yet been approved for marketing in China. The drug needs to be injected subcutaneously, and the dosage is adjusted according to the patient's age and condition. Special attention should be paid when using it in special groups such as pregnant women, lactating women and children. The following will introduce the relevant information of aftase alpha in detail from three aspects: price, usage and medication for special groups.

What is the price of genuine Aftase α in 2025?

The original drug is produced by Ruisong Pharmaceuticals in the United States. The latest price information in 2025 shows that the price of 18mg/0.45mL/box is approximately US$13,204. Since the drug is not yet available in the country, patients need to purchase it through overseas channels.

18mg/0.45mL specification price

The price of 18mg/0.45mL/box of aftase α is approximately US$13,204. It is suitable for adult standard dose treatment and requires 2-3 boxes per month. Long-term treatment costs are high and imposes a greater financial burden on patients.

Price of other specifications

Afotalase α is also available in 28mg/0.7mL, 40mg/mL and 80mg/0.8mL. The price varies depending on the specifications. The 80mg/0.8mL specification is suitable for patients with larger body weight, but is prohibited for patients weighing less than 40kg.

The high price of aftase alpha limits its widespread application worldwide, and patients are looking forward to more economical alternative treatment options in the future.

Usage of afotalase α

Afotalase α needs to be injected subcutaneously. The dosage should be adjusted according to the patient's age and condition. Doctor's instructions must be strictly followed.

Perinatal/infancy-onset HPP dose

The recommended dose is 6 mg/kg per week, which can be subcutaneously injected at 2 mg/kg three times per week or 1 mg/kg six times per week. If efficacy is insufficient, the dose can be increased to 9 mg/kg per week.

Dosage of adolescent-onset HPP

The recommended dose is the same as in infancy, 6 mg/kg per week, divided into injections. Injection site reactions may limit tolerance of frequent injection regimens and require individualized adjustments.

The use of aftase alfa must be carried out under the guidance of experienced medical professionals. Patients are not allowed to adjust the dosage or injection method by themselves.

Medicine for special groups of aftase α

Some special groups need to pay special attention to medication safety when using aftase α. The following are the main precautions.

Pregnant and lactating women

Animal experiments have shown no teratogenicity or embryotoxicity, but there is a lack of human data. It is recommended to decide whether to use the drug after weighing the risks and benefits. There is no human milk excretion data for lactating women, and the health of the mother and baby needs to be taken into consideration when deciding whether to take medication or suspend breastfeeding.

Use by children and the elderly

The safety and effectiveness of use in children have been established in 89 pediatric patients and can be used for children of all ages, including newborns. There are insufficient data from clinical studies in elderly patients 65 years and older to determine whether they respond differently.

Special groups must strictly follow the doctor’s instructions when using aftase alpha, and they are not allowed to adjust the medication plan on their own. If you feel any discomfort during the medication, you should seek medical advice promptly.